Clinical Trial Update: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study of EMB-06 for relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• EMB-06

Snippet

Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED